Well-conducted Phase II clinical trials provide the data required to determine if there’s a case to be made for progressing a drug candidate into Phase III trials. However, Phase II success rates are lower than at any other phase of development. These larger late phase studies present unique challenges and even greater opportunities for the use of eSource to reduce costs and timelines.